According to a recent phase 2 study, denosumab is an effective treatment for patients with giant-cell tumor of bone (GCTB). In this study, results of which are published in The Lancet Oncology, 532 adult and skeletally mature adolescent patients with histologically confirmed and radiographically measurable GCTB were enrolled. In order to be eligible, participants had to be at or above the age of 12 years, weigh at least 45 kg, have a Karnofsky performance status of 50% or higher (Eastern Coopera...

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...

Because most patients with small-cell lung cancer (SCLC) present with extensive-stage disease—in which the cancer has spread to both lungs or throughout the body—survival rates are poor, and there is a need to develop alternative treatments to improve outcomes. In their study now published in The Lancet, Luis Paz-Ares, MD, and colleagues found that in patients with extensive-stage SCLC (ES-SCLC), the addition of the immunotherapy drug durvalumab to a chemotherapy regimen of platinum/etoposide si...

The phase 3 CASPIAN trial reports that adding durvalumab (Imfinzi®, AstraZeneca) to etoposide and a platinum therapy improves overall survival in patients with extensive-stage small-cell lung cancer (ES-SCLC). Many patients with small-cell lung cancer do not receive a diagnosis until after their disease has already reached the extensive stage, at which point the prognosis is poor. Because immunotherapy has shown some activity in ES-SCLC, the researchers of the CASPIAN trial assessed the efficacy...

​ Many patients with cancer experience infections requiring treatment. However, David Pinato, MD, MRes, PhD, and colleagues recently found that in patients with non-small cell lung cancer (NSCLC), melanoma, and other tumor types, broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worsened overall survival (2 vs 26 months) and increased the risk of treatment-refractory disease . In this interview with i3 He...